JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Catalyst Pharmaceuticals Inc

Închisă

SectorSănătate

20.72 -0.86

Rezumat

Modificarea prețului

24h

Curent

Minim

20.66

Maxim

20.94

Indicatori cheie

By Trading Economics

Venit

-4.6M

52M

Vânzări

5.1M

147M

P/E

Medie Sector

12.733

37.461

Marjă de profit

35.553

Angajați

181

EBITDA

5.9M

79M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+57.37% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-79M

2.6B

Deschiderea anterioară

21.58

Închiderea anterioară

20.72

Sentimentul știrilor

By Acuity

24%

76%

59 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Catalyst Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 oct. 2025, 20:49 UTC

Câștiguri

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Câștiguri

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Câștiguri

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Câștiguri

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Câștiguri

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Câștiguri

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Câștiguri

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Sees 4Q Adj EPS 8c >INTC

Comparație

Modificare preț

Catalyst Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

57.37% sus

Prognoză pe 12 luni

Medie 33 USD  57.37%

Maxim 35 USD

Minim 31 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCatalyst Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 24.28Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

59 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
help-icon Live chat